

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

# 5.8.01

Applicant(s): Steven L. Krill *et al.*

Serial No.:

Filing Date: November 8, 2000

Title: SOLID DISPERSION  
PHARMACEUTICAL FORMULATIONS

Docket No.: 6488.US.02

Date: November 10, 2000

Certificate of Mailing Under 37 C.F.R. §1.10

Express Mail No. EL 384 167 796 US

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below as Express Mail Post Office to Addressee Service under 37 CFR 1.10 addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

Date of Deposit: November 10, 2000

*Kathleen T. Litz* 11/10/2000  
Kathleen T. Litz Date

jc992 U.S. PTO  
09/709829  
11/10/00

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)(3)

The Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

The following information is submitted pursuant to 37 C.F.R. §§1.97 and 1.98 in accordance with Applicants' duty of disclosure under 37 C.F.R. §1.56. This submission is not an admission that the documents cited herein are prior art as to the invention claimed.

The following references are known to applicants:

- 1.D. Kempf, *et al.*, U.S. Patent No. 5,889,051, issued March 30, 1999.
2. Miyamoto, European Patent Application No. EP 0852 140 A1, published 08 July 1998
3. Ostovic, *et al.*, International Patent Application No. WO97/46222, published 11 December 1997
4. Miyamoto, International Patent Application No. WO97/06781, published 27 February 1997
- 5.W. L. Chiou, *et al.*, "Pharmaceutical Applications of Solid Dispersion System", JOURNAL OF PHARMACEUTICAL SCIENCES, 60 (9), (1971), 1281-1302
- 6.J. L. Ford, "The Current Status of Solid Dispersions", PHARM ACTA HELV. 61. Nr.3, (1986) 69-88
- 7.B. J. Aungst, *et al.*, "Improved Oral Bioavailability of an HIV Protease Inhibitor Using Celucire 44/14 and Labrasol Vehicles", B.T. GATTETOSSE, 87 (1994), 49-54
- 8.B. J. Aungst, *et al.*, "Amphiphilic Vehicles Improve the Oral Bioavailability of a Poorly Soluble HIV Protease Inhibitor at High Doses", INTERNATIONAL JOURNAL OF PHARMACEUTICS, 156 (1997) 79-88

These reference do not disclose or suggest the invention claimed in this application.

Copies of these references are enclosed. Applicants respectfully request that these references be made of record.

In view of the foregoing information, favorable consideration of the claims in the Application is respectfully requested.

Abbott Laboratories  
D-377/AP6D-2  
100 Abbott Park Road  
Abbott Park, IL 60064-6050  
Telephone: (847) 937-9516  
Facsimile: (847) 938-2623

Respectfully submitted,  
Steven L. Krill *et al.*

*Steven R. Crowley*  
Dr. Steven R. Crowley  
Registration No. 31,604  
Agent for Applicant(s)